BACKGROUND: Several distinct risk factors for arrhythmia recurrence and mortality following ventricular tachycardia (VT) ablation have been described. The effect of concurrent risk factors has not been assessed so far; thus, it is not yet possible to estimate these risks for a patient with several comorbidities. The aim of the study was to identify specific risk groups for mortality and VT recurrence using the Survival Tree (ST) analysis method.
R
adiofrequency catheter ablation has been shown to reduce ventricular tachycardia (VT) burden and appropriate implantable cardioverter defibrillator (ICD) therapies in patients with structural heart disease. [1] [2] [3] Catheter ablation has become a widespread treatment for postinfarct VTs during the past decade. 4, 5 Despite several improvements in techniques [6] [7] [8] [9] [10] and technologies, [11] [12] [13] [14] patients are still exposed to a significant risk of recurrence and mortality after VT ablation. Several studies have attempted to identify predictors of adverse outcomes in single-center and multicenter studies. However, a preprocedural model that estimates patient's risk of 1-year VT recurrence and mortality has not been developed yet.
The aim of this study was to identify clinical and demographic characteristics allowing to classify patients into subgroups with distinct risks for 1-year VT recurrence and mortality after catheter ablation for VT associated with structural heart disease.
METHODS

Study Design
The authors declare that all supporting data and methods are available within the article. The International VT Ablation Center Collaborative Group consists of 12 international sites that specialize in VT management with a developed protocol for data sharing. 12 Data about 1251 patients undergoing catheter ablation for previous sustained VT in the setting of structural heart disease between 2002 and 2013, with complete data for the variables of interest, were retrospectively collected and analyzed. Structural heart disease was defined as ischemic cardiomyopathy (ICM) and nonischemic cardiomyopathy (NICM) with left ventricular ejection fraction (LVEF) <55%, with scar confirmed during electroanatomic mapping; patients with LVEF >55% were included in cases of right ventricular predominant cardiomyopathy and hypertrophic cardiomyopathy. The diagnosis of ICM was established by prior history of myocardial infarction, or fixed perfusion defect correlated with coronary stenosis or prior coronary artery intervention. Causes for NICM included idiopathic dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, valvular cardiomyopathy, myocarditis, hypertrophic cardiomyopathy, sarcoidosis, familial, and left ventricular noncompaction. Electrical storm (ES) was defined as ≥3 VT/ ventricular fibrillation (VF) episodes within 24 hours. Baseline characteristics of patients are shown in Table 1 . The study was approved by the institutional review boards of the respective participating centers.
Ablation Procedure
Procedural details and ablation strategies have been previously described. 12 Contemporary approaches for substratebased ablation guided by electroanatomic mapping, pace mapping, and when feasible, activation and entrainment mapping, were performed across all centers.
Programmed electrical stimulation (PES) using up to 2 sites, 2 drive trains, and triple extrastimuli was performed for induction of VT. When a 12-lead ECG of spontaneous VT was available, clinical VT was defined by match in all 12 leads. In the absence of 12-lead ECG of the spontaneous VT, clinical VT was defined as the one matching the morphology and cycle length within 30 ms of the ICD stored electrograms from spontaneous VT episodes. The remaining sustained monomorphic VTs induced by PES were defined as nonclinical but were routinely targeted for ablation. Ablation of areas of late activation or local conduction delay as evidence by split, fractionated, or isolated late potentials was performed at the discretion of the treating physician. 8, 10, 15, 16 After ablation, PES was repeated unless prohibited by hemodynamic instability or procedure duration concerns. Acute procedural success was defined as elimination of all inducible sustained monomorphic VTs. Partial success was defined as elimination of all clinical VTs but with monomorphic VT still inducible. Failure was defined as persistent inducibility of the clinical VT.
Outcomes
Patients were followed up by ICD interrogation at 3, 6, and 12 months. For patients not followed up at an International VT Ablation Center Collaborative Group center, referring cardiologists were contacted and ICD interrogations reviewed. Remote control follow-ups were carefully checked for VT recurrence. Telephone interviews were also routinely performed with patients or family members. Recurrent VT/VF was defined as documented VT/VF lasting >30 seconds, or any appropriate ICD therapy including antitachycardia pacing. Study end points were VT recurrence after the last ablation procedure, death. Antiarrhythmic therapy after ablation was at the discretion of the treating physician.
WHAT IS KNOWN?
• Radiofrequency catheter ablation has been shown to reduce ventricular tachycardia burden and appropriate implantable cardioverter defibrillator therapies in patients with structural heart disease.
• Patients are still exposed to a significant risk of recurrence and mortality after ventricular tachycardia ablation.
WHAT THE STUDY ADDS?
• The present study is the first to derive and validate a risk model that provides estimates of ventricular tachycardia recurrence and mortality with an effective classification tree.
• The decisional tree identified left ventricular ejection fraction as the most informative variable in predicting both recurrence and death.
• The model helps to identify subset of patients with several comorbidities who may require additional interventions to improve procedural efficacy and outcomes.
• Preoperative risk stratification could help counseling for patients and their families and also planning supplementary care before and after the procedure.
Primary efficacy outcome was 1-year all-cause mortality after VT ablation. Secondary outcomes were the 1-year incidence of VT recurrence and time to VT recurrence. Clinical outcomes of patients are shown in Table 2 . Recurrent VT/VF was defined as documented VT/VF lasting >30 seconds or any appropriate ICD therapy including antitachycardia pacing. Data were pooled into a central database for analysis.
Statistical Analysis
Survival tree (ST) analysis was applied to discover groupings of subjects with homogeneous survival outcome, using information provided by clinical and procedural covariates. 17 ST is a machine learning procedure based on binary recursive partitioning of a group of subjects, aiming at the choice of optimal cut points for binary, ordinal, or continuous covariates, which maximizes split criterion. 18 The output is a decision tree, consisting of nodes and leaves, with each leaf indicating a class or a predicted outcome value (Figure 1 ).
Statistical analysis was performed on a cohort of patients with complete data for all covariates. The root node of the tree (top of the tree), comprises all the observations; it is split into daughter nodes; the splitting process continues recursively for each subsequent node. The following covariates, showing statistical significance in previously published articles, 12, [19] [20] [21] [22] [23] were considered for the preoperative analysis: sex, age, hyperlipidemia, hypertension, diabetes mellitus, atrial fibrillation, chronic kidney disease, New York Heart Association Functional Classification (NYHA), type of cardiomyopathy (ICM and NICM), LVEF, use of ≥2 antiarrhythmic drugs, type of cardiac device already implanted before the ablation (none, ICD, cardiac resynchronization device [CRT]), previous ICD shocks, ES, occurrence of a previous VT ablation. Age was categorized into 3 classes (<65, 65-79, and ≥80 years) based on preliminary ST analyses that included age as a continuous variable. At each step of the tree-growing procedure, the algorithm selected the best predictor and the best splitting cutoff according to an exponential model, as described in rpart. 24 At the end of the process, subjects with similar survival profiles end up in the same terminal node. A variable may be chosen as best predictor several times throughout the procedure.
Patients were classified in 3 risk groups based on hazard ratio (HR) for VT recurrence and mortality risk scores of the final leaves of the trees: low ≤0.7, medium: 0.8-1.4, and high >1.4. Kaplan-Meier estimates of VT recurrence and death in groups derived from each ST analysis were obtained and compared by log-rank test.
Random survival forests approach was applied to internally validate the results, by evaluating prediction accuracy, robustness of the results, and assessing covariate importance. 18, 25, 26 In the present study, 5000 bootstrap samples were drawn from the original data, and an ST was derived for each bootstrapped sample without applying pruning. In the construction of each tree, at each node of the tree grown on bootstrapped data, the procedure randomly selected a narrowed set of predictors on which to base splitting. Hence, the splitting variable was searched within the reduced set of predictors. 26 A final prediction was then obtained by combining each individual tree.
Predictive value for each variable in the tree was assessed by evaluating the minimal depth 26 that measures the depth of the first split with respect to the root node; the shorter is the split, the more predictive is the variable.
In previous studies, acute VT inducibility following ablation was shown to have an impact on VT recurrence and survival. 12, 19 To check whether risk stratification early after the ablation using PES could add benefit to the present analysis of procedure-related covariates, we developed additional models including PES in the list of variables analyzed by ST and random survival forest. Statistical analysis for the postprocedure model was performed on a cohort of 1210 patients with complete data for all analyzed covariates.
We calculated the PAAINESD score 27 for the International VT Ablation Center Collaborative Group cohort and compared its prediction of mortality to the I-VT (International Ventricular Tachycardia) score using receiver operating characteristic curves. To evaluate if the in low/mid/high categories corresponded to an increasing rate pattern of VT recurrence and death, the model was externally validated in a population of consecutive patients with structural heart disease, undergoing VT ablation at San Raffaele Hospital between January 2014 and February 2017; population characteristics are shown in Table I in the Data Supplement. Analyses were performed using R statistical software (version 3.4.2). 28 In particular, the survival 29 along with rpart 24 and randomForestSRC 30 packages were used to implement survival analysis, obtain STs, build random forest, and derive variable importance, respectively. The significance level was considered to be <0.05.
RESULTS
Risk of VT Recurrence
ST analysis ( Figure 2A ) showed a major impact of LVEF on outcomes; an LVEF of 30% was identified as the best threshold to classify risk of both recurrence and death. Patients with LVEF <30% had a high VT recurrence risk (HR=1.6), compared with patients with LVEF ≥30% (HR=0.7). Among those with LVEF <30%, patients with a previous ablation had the highest risk of VT recurrence after the index procedure (HR=2); among patients with LVEF ≥30%, the absence of an ICD was associated with lower risk (HR=0.38 versus 0.81). Further risk stratification for VT recurrence in patients with LVEF ≥30% was provided by incorporation of type of cardiomyopathy ( The root note of the tree (shown on top) comprises all the patients; it splits into daughter nodes; the splitting process continues recursively for each subsequent node. Subsequent splitting allows for the identification of subgroups with homogeneous risk profile. At the top of the tree hazards ratio (HR) is 1 because the baseline hazard of the entire cohort of the study is used as reference. 
2).
Based on the HR, we outlined 3 profiles ( Figure 2B ): low risk (HR <0.7, green boxes), medium risk (HR between 0.7 and 1.4, yellow boxes), and high risk (HR >1.4, red boxes). Based on the final branches of the ST analysis, patients with LVEF ≥30%, without ICD, and with ICM were assigned to the low-risk group, that experienced a very low risk of VT recurrence (HR=0.086, no patients with VT recurrences after ablation among 33 in the group). Additionally assigned to the low-risk group were the following patients with LVEF ≥30%, without ICD, and with NICM (HR=0.48); patients with LVEF ≥30%, with and ICD or CRT, and with ICM (HR=0.63); patients with LVEF ≥50%, with and ICD or CRT, and with NICM (HR=0.59).
In the medium-risk group were assigned patients with LVEF 30% to 50%, with an implanted ICD or CRT device and NICM (65 of 224 experienced recurrence, HR=1.2); and patients with LVEF <30% without a previous ablation (89 patients with recurrences among 280 in the group; HR=1.3).
In the high-risk group for VT recurrence were patients with LVEF <30% who had a previous ablation (HR=2). Complete risk stratification for all groups is shown in Figure 2A . The 3 risk groups showed significantly different VT free survivals by log-rank test (Figure 2B ; P<0.001).
Risk of Death
The ST for mortality analysis ( Figure 3A) showed that, similar to VT recurrence analysis, a cutoff of 30% for LVEF was the primary classification node for VT patients. Among the lower-risk cohort, the occurrence of a previous ablation led to further categorization of 2 low-risk groups: patients without a previously failed VT ablation had the lowest 1-year risk of death (0.96%, HR=0.088) that was significantly better than those with a previous VT ablation (5.2%; HR=0.45).
Patients with LVEF <30% had a higher risk of death during the first year after the procedure (HR=2), as compared with those with LVEF ≥30 (HR=0.2). In this cohort of patients, the second decisional node was a history of ES: patients with a previous ES were classified in the high-risk group (HR=2.8). In the cohort of patients with LVEF <30% and the absence of ES, the further classification was provided by the presence of LVEF <14%, age, and ICD. Noticeably, ST identified patients with LVEF between 14% and 30%, no VT storm, an ICD, and age ˂80 years, as having a low 1-year risk of death (12/174 died, 6.9%; HR=0.58). All other patients with LVEF <30 were classified in the high risk of death group, with the highest-risk cohort being those with LVEF <14% (HR=4.3). These 3 groups showed significantly different 1-year survivals by log-rank test ( Figure 3B, P<0.001 ).
An online calculator for the assessment of recurrence and death risk after VT ablation is available at www.vtscore.org.
Risk Reassessment After VT Ablation
Results of PES after ablation were previously hypothesized to have an impact on VT recurrence and survival prediction. To check whether PES should be considered for accurate risk stratification after the procedure, we developed 2 additional survival models including postprocedure covariates.
For VT recurrence ( Figure 4A ), after the first split on LVEF (same as obtained in the preprocedure tree), PES was a relevant predictor of risk, both in high-and lowrisk groups. In particular, patients with clinical VT still in- ducible and those not tested showed a higher risk of VT recurrence. Other variables detected by the tree were presence of ICD, age, and previous ablation.
For the death analysis ( Figure 5A ), PES also appeared as a second split but only in the high-risk group (LVEF <30). In this case, patients with no inducible VTs were reclassified as low risk. The remaining splits are similar to those based on preprocedure variables alone.
Also in the postprocedure variable analysis, KaplanMeier analysis of the risk groups showed statistically different survivals (all log-rank P<0.001; Figures 4B and 5B).
Model Validation
In the VT recurrence analysis, LVEF had the highest importance (minimal depth=0.058), followed by the presence of an ICD (minimal depth=0.117); these variables provided major splits in the ST, confirming their importance in discriminating the risk of recurrence among VT patients. The information about minimal depth for each variable is reported in Figure I in the Data Supplement. In the risk of death analysis, LVEF showed the highest importance (minimal depth=0.062); other variables showing up in the tree ( Figure 3A : ES, previous ablation, age, and device) had a high importance ( Figure  IB in the Data Supplement). According to random survival forest, also NYHA had a high importance (minimal depth=0.118, second in rank among the variables); it did not show up in the trees because NYHA resulted to be a surrogate variable for the primary split. From a practical point of view, in the absence of information on LVEF, which provides the best classification, NYHA may be used for stratification, with NYHA ≥3 patients having a worse prognosis than those with NYHA ≤2.
When performing internal validation of the postprocedure trees, the result of PES showed a high importance in both the recurrence (minimal depth=0.061) and survival (minimal depth=0.082), being ranked second just after LVEF ( Figure IC and ID in the Data Supplement).
The importance of including PES as a predictor is also shown by the increase of accuracy in the prediction of both VT recurrence and mortality; in our sample, 29.2% of patients classified in the high-risk group by the preprocedure risk stratification died, while the mortality increased to 33.7% in the group of patients classified in the high-risk group by the postprocedure score (P<0.01; Table 3 ). When considering VT recurrence, the prediction improvement was visible in low-and midrisk groups: VT recurrence was 15.4% and 30.6% in patients classified in the low-and medium-risk groups by the preprocedure score; it decreased to 7.5% and 22.9% respectively, when PES was included in the model (P<0.01).
The current scores, both before and after the procedure (including PES), were associated by receiver operating characteristic analysis to a higher prediction of mortality, as compared PAAINESD score (area under the curves 0.82 versus 0.71 and 0.84 versus 0.71, respectively; P<0.001 for both comparisons; Figure 6 ). When the model was applied to a different population for external validation, 26.5% of patients classified in the high-risk group by the preprocedure risk stratifica- Figure 1 . Left ventricular ejection fraction (LVEF) remains as the most predictive variable also for postoperative risk estimation. In patients with LVEF <30%, the result of programmed stimulation after the procedure (PES), diabetes mellitus (DM), ES (electrical storm), age provided further risk stratification. In patients with LVEF ≥30% occurrence of a previous ablation (Previous Abl) was identified as further splitting variable. B, (Right): Kaplan-Meier estimates with 95% CIs of VT recurrence for patients with low (green line), medium (yellow line), and high profile (red line). C-VT indicates clinical ventricular tachycardia inducible after the ablation; NC-VT, nonclinical VT inducible after the ablation; No VT, absence of any VT inducible at programmed stimulation after the ablation; and NT, not tested. tion died within 1 year, while the mortality increased to 34.3% in the group of patients classified in the high-risk group by the postprocedure score (Table II in the Data Supplement). Among the same population, patients classified in low-and high-risk groups by the preprocedure score showed a 1-year VT recurrence of 20.8% and 28.5%; when PES was included in the model, 1-year VT recurrence in low-and mid-risk groups were 10.5% and 27.2%, respectively.
DISCUSSION
In this study, we presented the first available prediction model for 1-year recurrence and mortality after VT ablation. The model was derived and validated from the largest available and well-characterized population of patients undergoing VT ablation in the setting of structural heart disease, treated at 12 international sites. Estimates were obtained from routinely collected clinical and procedural parameters, thus not requiring any additional examinations outside current clinical practice. The broad patient inclusion criteria of the study and the enrollment of consecutive patients following real-world practice allowed the study of a wide spectrum of conditions associated with VT; thus, the model could be applied to current practice in adult patients with an indication for VT ablation.
In the I-VT score cohort, participants had a 1-year recurrence risk of 25.8% and a 1-year risk of death of 12.2%. The decisional tree identified a gradient of risk across the patients undergoing VT ablation, ranging from negligible to 42.8% for recurrence and from negligible to 62.5% for 1-year mortality; the highestrisk groups, thus showed an HR for recurrence and for In the A only preprocedure variables were included in the I-VT score; in B, both preprocedure and postprocedure variables were included in the I-VT score. mortality respectively 23 and 49× higher than lowrisk groups. The inclusion of the results of the PES after ablation in the model allowed a more refined risk estimation. Current clinical guidelines recommend catheter ablation in patients with recurrent ICD shock and consider the procedure after a first episode of sustained VT in patients with an ICD. 5 However, no further prognostic information is provided to support clinical decision making. Our findings provide a strong step toward identifying patients at risk of death during the first year after VT ablation; they can help physicians to counsel patients before VT ablation procedure and also to target supplementary strategies during or after the procedure, aimed at prevention of death in the highest-risk subgroups. In the ST analysis LVEF, previous ablation, type of cardiac device, and type of cardiomyopathy were identified as the best predictors for 1-year VT recurrence; LVEF, ES, age, and type of cardiac device were selected as best predictors of 1-year survival.
Significance of LVEF
LVEF appeared as the most informative variable in predicting both recurrence and death, thus appearing in all the decisional trees as the first branch. LVEF was used as a continuous variable, allowing the investigation of a gradient of risk across a broad range of values, rather than a priori dichotomizing risk; optimal cut points were derived by the ST procedures. LVEF <30 identified a high-risk population; analysis of additional variables, both in the LVEF <30 and LVEF ≥30 groups, allowed a more accurate risk stratification.
Although several markers of sudden cardiac death have been proposed, including signal-averaged ECG, 31 heart rate variability, 32 baroreflex sensitivity, 33 QRS prolongation, 34 and T-wave alternans, 35 none of those is currently used in clinical practice. 36 LVEF is the only widely accepted predictor of death in patients with structural heart disease; it has been used for more than a decade in determining eligibility for primary prevention ICD 37, 38 and is still recommended by current clinical guidelines to identify patients who need ICD implant because of high risk of developing VT/VF. 39 The reproducible prediction power of LVEF was confirmed by a recent systematic review that highlighted the inclusion of LVEF in 58% of the 43 published models for death in HF. 40 
Evaluation of Patients With Multiple Comorbidities
In previous studies, advanced heart failure status (NYHA class IV), 21 female gender, 23 history of a previous VT ablation, 22 and presentation with ES 19 were associated to poor outcomes. The analysis of subgroups of patients sharing one common characteristic provides the opportunity to focus the point of view on the specific field that is analyzed in depth; however, this approach tends to hide the multiple interactions between the various characteristics and comorbidities that constitute the full portrait of each patient. By examining simultaneously all variables and selecting the best splits, the ST analysis may identify subtle differences between patient profiles and maximizing the survival stratification.
About one-third of patients are exposed to a 1-year risk of death higher than 20% (high-risk group). Comprehensive counseling providing realistic expectations for patients and their families is an important part of the medical mission; this is especially true in situations in which there is greater risk of an unfavorable outcome as in patients with very low LVEF, previously failed ablations, advanced age, and ES. The present model helps to identify this particular subset of patients who may require additional interventions to improve procedural efficacy and outcomes. Because all patients in the study underwent catheter ablation, a high-risk score for arrhythmia recurrence or death after the procedure is not a mandatory criterion for denying the treatment. A physician might advise patients at high risk for recurrence on the possible need for a redo procedure already during the preprocedure counseling. Patients with a high risk of death may benefit of a proactive institution of therapy, including mechanical hemodynamic support, that is recognized to improve outcomes. 41, 42 In patients with untreatable VT after a previous ablation and a high risk for recurrence and death, heart transplant might be considered. 43 Results of patients risk stratification after the procedure may also be used for individualizing follow-up strategies, thus suggesting more careful monitoring in patients at high risk for recurrence.
Comparison With Existing Methods and Models for Risk Prediction
There is an increasing interest in the development of prediction models to justify medical treatments (CHA2DS2-VASc 44 and TIMI [Thrombolysis In Myocardial Infarction] score 45 ) or to predict outcomes. STs are powerful and effective tools useful to identify homogeneous groups of patients with different risk profiles. With respect to standard Cox regression models, they provide several advantages: they automatically select variables which allow to best discriminate among groups, identify optimal cutoffs for the examined variables and uncover interactions among variables without the need to directly specify them in the model.
Widespread application of risk stratification models in routine clinical practice is usually inhibited by the feeling that they are time-consuming or providing lowvalue information. 46 The Seattle score 47,48 included 14 continuous and 10 categorical values, thus making it impractical for computation by hand. In 43 previously published models for prediction of death in heart failure, the median number of final predictors was 9 (range: 3-317). 40 Identification of only the informative variables and improvement in techniques for easier visualization of the risk profile have been acknowledged to favor the clinical application of the tools. 40 The current decisional tree requires only the 6 variables selected among 15 analyzed, based on variable importance; variables not improving the classification were discarded by the procedure.
The previously developed PAAINESD score 27 can be used for the evaluation of 30-day mortality after VT ablation. The current I-VT score confirms that LVEF, age, ES, type of cardiomyopathy and diabetes mellitus, already present in the PAAINESD score are important predictors of poor outcome; as compared with the PAAINESD score, I-VT score provides a longer timeframe (1 year) estimation and a more accurate prediction of mortality. When applied to an external population, the I-VT score proved to be effective in predicting VT recurrence and mortality; similarly to the results obtained in the training sample, patients categorized as high risk had a higher rate of recurrence and death then low-/ mid-risk groups.
Limitations
This study was a retrospective analysis of data from high volume, tertiary-referral ablation hospitals. As such, it is possible that a referral bias and the wide lifespan of the study may limit the generalizability of our results beyond centers with extensive experience in VT ablation. Antiarrhythmic drug therapy and ICD therapies programming were left to the discretion of the treating physicians and could influence outcomes. In particular, VT recurrence may have been underreported in patients without an ICD; on the other side, inflated recurrence rates in patients with ICD implants might be due enhanced detection and rapid treatment by ICD also for VTs that could otherwise terminate spontaneously. However, the sample size larger than previously published studies is a major strength. Future studies should test prospectively the present risk model.
Conclusions
The present study is the first to derive and validate a risk model that provides estimates of VT recurrence and mortality with an effective classification tree. Preoperative risk stratification could help counseling for patients and their families and also planning supplementary care before and after the procedure.
An online calculator for the assessment of recurrence and death risk after VT ablation is available at www.vtscore.org. 
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